Genflow Biosciences Plc
London Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Genflow Biosciences plc functions as a pioneering biotechnology enterprise, concentrating its efforts on creating advanced gene therapies designed to address the mechanisms of biological aging, thereby aiming to prolong health span and diminish the prevalence of age-related conditions. The company's primary therapeutic candidate, GF-1002, is an adeno-associated viral vector-based gene therapy suspension, intended for intravenous administration. This lead program is actively progressing toward clinical trials for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent liver disease for which there are currently limited effective treatments. Further advancing its innovative pipeline, the firm is also developing GF-3001, a formulation providing topical delivery of the SIRT6 gene to the skin, and GF-1004, a specialized non-human anti-aging gene therapy designed for veterinary applications in dogs, which has recently shown promising results in proof-of-concept studies. Established in 2020, Genflow Biosciences maintains its corporate headquarters in London, United Kingdom, with integral research and development operations based in Belgium.
Micron shares rise on Anthropic AI infrastructure partnership
Genflow Biosciences says chair will attend bio conference this week
Genflow to present beagle gene therapy data at longevity summit
Genflow surges 14% as animal health giants circle canine ageing gene therapy
HeLIX Exploration boosted by new US Air Force hydrogen venture
Genflow Biosciences expands SIRT6 patent protection into muscular diseases
Genflow CEO on promising SLAB trial data - ICYMI
UK IPO market limps through Q1 with just two listings as geopolitical strain and AI sell-off bite
Rezolve AI launches hostile takeover bid for Commerce.com
Genflow reports sustained safety and efficacy three months after gene therapy dosing in dog trial
Delta Air Lines shares take flight on first quarter earnings beat
February jobs shock signals slowing economy: analysts
Genflow Biosciences raises £800,000 to fund gene therapy programmes
FTSE 100 Live: Iran war affects airlines and banks, natural gas prices soar
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor
Genflow Biosciences: AGM and partnership strategy - ICYMI
Nasdaq leads market declines as AI concerns weigh on tech stocks
AI-driven market disruption could hit loans and high-yield credit, UBS says
Pri0r1ty Intelligence shares rise as it launches new AI product
Genflow shares jump 19.5% on positive interim data from dog gene therapy trial